Helping to improve your quality of life.
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The company selects drugs from its extensive portfolio with the potential to be safe and effective for improving patient care while significantly increasing near-term value for partners and payers. The product pipeline includes new uses for previously approved drugs, some of which are now starting clinical trials, and new molecular entities (“NMEs”).
A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize the company’s product development programs. Learn More
Product Pipeline
Learn More About:
Diabetic Retinopathy
A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness
Diabetic Nephropathy
A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis
| AMPE Stock Quote - delayed | ||
| Last | Change | |
| AMPE.OB | 1.90 | 0.00 (0.00%) |
Ampio News
08/03/2010 | Press Release
Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
07/22/2010 | Press Release
Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina
05/10/2010 | Press Release
Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer